New cocktail of drugs takes on tough pancreatic cancer
NCT ID NCT04999969
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing a combination of two experimental drugs (AZD0171 and durvalumab) plus standard chemotherapy in 126 people with advanced pancreatic cancer. The goal is to see if the combo is safe and helps patients live longer. Participants must have metastatic disease and provide tumor samples for analysis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD0171, durvalumab, gemcitabine, and nab-paclitaxel
What this could lead to
If successful, this combination could offer a new treatment option for advanced pancreatic cancer, potentially improving survival rates.
What could go wrong
This is an early phase II trial with only 126 participants, so results may not apply to all patients. The combination may cause significant side effects, and it is not yet known if it works better than standard care alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
La Jolla, California, 92037, United States
-
Research Site
Los Angeles, California, 90025, United States
-
Research Site
Orange, California, 92868, United States
-
Research Site
Ventura, California, 93003, United States
-
Research Site
Atlanta, Georgia, 30318, United States
-
Research Site
Coeur d'Alene, Idaho, 83814, United States
-
Research Site
Boston, Massachusetts, 02114, United States
-
Research Site
Ann Arbor, Michigan, 48109, United States
-
Research Site
Grand Rapids, Michigan, 49503, United States
-
Research Site
Buffalo, New York, 14263, United States
-
Research Site
New York, New York, 10065, United States
-
Research Site
Portland, Oregon, 97239, United States
-
Research Site
San Antonio, Texas, 78229, United States
-
Research Site
Charlottesville, Virginia, 22908, United States
-
Research Site
Seattle, Washington, 98195, United States
-
Research Site
Madison, Wisconsin, 53792, United States
-
Research Site
Barrie, Ontario, L4M 6M2, Canada
-
Research Site
Toronto, Ontario, M4N 3M5, Canada
-
Research Site
Toronto, Ontario, M5G 2M9, Canada
-
Research Site
Seongnam-si, 13620, South Korea
-
Research Site
Seongnam-si, 463-712, South Korea
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Seoul, 06591, South Korea
-
Research Site
Badalona, 08916, Spain
-
Research Site
Barcelona, 08035, Spain
-
Research Site
Madrid, 28027, Spain
-
Research Site
Madrid, 28034, Spain
-
Research Site
Madrid, 28041, Spain
-
Research Site
Madrid, 28050, Spain
-
Research Site
Majadahonda, 28222, Spain
-
Research Site
Pamplona, 31008, Spain